8-K: Neumora Reports Q2 2025 Results, Advances Pipeline

Neumora Therapeutics announced its second quarter 2025 financial results and provided key updates on its clinical pipeline, including prioritizing obesity for NMRA-215 and anticipating multiple data readouts.

Summary

• Neumora Therapeutics reported a net loss of $52.7 million for the second quarter ended June 30, 2025, an improvement from a net loss of $58.7 million for the same period in 2024.
• Research and development expenses decreased to $38.7 million in Q2 2025, down from $48.6 million in Q2 2024, primarily due to reductions in stock-based compensation, personnel-related expenses, and clinical trial costs.
• General and administrative expenses remained stable at $15.3 million in Q2 2025 compared to $15.2 million in Q2 2024.
• The company held $217.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which is expected to fund operations into 2027.
• A Phase 1 SAD/MAD study for NMRA-861 (M4 PAM) was initiated in July 2025, with data expected in the first quarter of 2026.
• Obesity has been prioritized as the lead indication for NMRA-215 (NLRP3 inhibitor), with preclinical diet-induced obesity (DIO) mouse model data expected in 2025 and clinical studies anticipated to begin in Q1 2026.
• Enrollment is ongoing for the Phase 3 KOASTAL program for navacaprant in Major Depressive Disorder (MDD), with topline data from KOASTAL-3 expected in Q1 2026 and KOASTAL-2 in Q2 2026.
• Data from a Phase 1b signal-seeking study of NMRA-511 for Alzheimer's Disease (AD) agitation is on track to be reported around the end of 2025.
• Neumora anticipates up to six clinical data readouts in patients over the next 18 months and expects to bring another M4 PAM, NMRA-898, into the clinic in 2025.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook, driven by significant pipeline advancements, multiple upcoming clinical data readouts, and a robust cash position extending into 2027. The reduction in net loss and R&D expenses also indicates improved financial management. While still operating at a loss, this is typical for a clinical-stage biopharma, and the progress outweighs the current financial burn.

Positives

• Net loss decreased by $6.0 million in Q2 2025 compared to Q2 2024, indicating improved financial performance.
• Research and development expenses saw a significant reduction of $9.9 million, reflecting cost efficiencies.
• The company maintains a strong financial position with $217.6 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2027.
• Multiple clinical data readouts are anticipated over the next 18 months, signaling significant pipeline progress and potential catalysts.
• Prioritization of obesity for NMRA-215 leverages the company's expertise in brain-penetrant chemistry for a large, underserved market.
• Initiation of the Phase 1 study for NMRA-861 and plans to advance NMRA-898 demonstrate active progression of the M4 PAM franchise.

Negatives

• The company continues to report a net loss of $52.7 million for the quarter, typical for a clinical-stage biopharmaceutical company without commercialized products.
• Cash, cash equivalents, and marketable securities decreased from $307.6 million at December 31, 2024, to $217.6 million at June 30, 2025, reflecting ongoing operational burn.

Risks

• Inherent uncertainty of clinical drug development and the unpredictability and lengthy process for obtaining regulatory approvals.
• Risks related to the timely initiation and enrollment in clinical trials.
• Reliance on third parties, including contract research organizations, for development activities.
• Potential for serious or undesirable side effects of therapeutic candidates.
• Risks related to the ability to utilize and protect intellectual property rights.
• Matters that could affect the sufficiency of capital resources to fund operations.

Future Outlook

The company anticipates a catalyst-rich period with up to six clinical data readouts in patients over the next 18 months. It expects to initiate clinical studies with NMRA-215 in the first quarter of 2026 and report data from the NMRA-861 Phase 1 study in Q1 2026. Topline data for navacaprant in MDD from KOASTAL-3 is expected in Q1 2026 and KOASTAL-2 in Q2 2026. Data for NMRA-511 in AD agitation is expected around the end of 2025. The current cash position is projected to fund operations into 2027.

Management Comments

• "Our R&D efforts have fueled multiple upcoming catalysts, with up to six clinical data readouts in patients over the next 18 months."
• "Additionally, we have productively advanced our pre-clinical pipeline, including prioritizing obesity as the lead indication for NMRA-215, our highly brain-penetrant NLRP3 inhibitor."
• "We expect to initiate clinical studies with NMRA-215 in the first quarter of 2026."
• "We are also looking forward to the upcoming clinical data readouts for navacaprant and NMRA-511, and we recently initiated a Phase 1 study with NMRA-861, our M4 PAM with potential best-in-class pharmacology."
• "We anticipate data from the NMRA-861 study in early 2026 and are excited about its potential as a therapeutic option for people with schizophrenia that addresses the need for more effective and better tolerated therapies beyond current antipsychotics and non-selective muscarinic agents."

Industry Context

Neumora's focus on brain-penetrant therapies for obesity (NMRA-215) addresses a significant unmet need, as current incretin therapies have limitations such as non-responders, GI adverse effects, and weight regain. The company aims to provide centrally acting drugs for weight loss. In schizophrenia, the development of NMRA-861 and NMRA-898 as M4 PAMs seeks to offer more effective and better-tolerated alternatives to existing antipsychotics and non-selective muscarinic agents, which often have significant side effects or limited efficacy for some patients. The pipeline also targets Alzheimer's disease agitation and Major Depressive Disorder, areas with high unmet medical needs.

Comparison to Industry Standards

• For obesity, the company highlights that up to a third of patients are non-responders to current incretin therapies and experience significant on-target GI adverse effects, with weight regain common after stopping these drugs. NMRA-215 aims to differentiate by being a highly brain-penetrant NLRP3 inhibitor, suggesting a novel mechanism of action compared to existing GLP-1 agonists.
• In schizophrenia, the company notes the need for more effective and better-tolerated therapies beyond current antipsychotics and non-selective muscarinic agents. NMRA-861 is positioned as a highly potent and selective M4 PAM with potential best-in-class pharmacology, aiming to improve upon the efficacy and tolerability profiles of current treatments.

Stakeholder Impact

• **Shareholders:** Positive impact due to significant pipeline progress, multiple upcoming catalysts, and extended cash runway, which reduces immediate dilution risk and provides clarity on future value drivers.
• **Patients:** Potential positive impact as the company advances therapies for underserved neurological and psychiatric conditions like MDD, AD agitation, schizophrenia, and obesity, offering hope for improved treatment outcomes.
• **Employees:** Continued stability and focus on R&D, potentially leading to growth opportunities within the company.
• **Creditors/Suppliers:** Stable financial position with extended cash runway suggests continued ability to meet obligations.

Next Steps

• Report data from preclinical DIO studies for NMRA-215 in 2025.
• Bring NMRA-898 into the clinic in 2025.
• Report data from Phase 1b signal-seeking study of NMRA-511 around the end of 2025.
• Initiate clinical studies with NMRA-215 in the first quarter of 2026.
• Report data from Phase 1 SAD/MAD study of NMRA-861 in the first quarter of 2026.
• Report topline data for navacaprant from KOASTAL-3 in the first quarter of 2026.
• Report topline data for navacaprant from KOASTAL-2 in the second quarter of 2026.
• Host a conference call and webcast on August 6, 2025, at 4:30 p.m. ET to review updates.

Key Dates

Recommendation

The filing indicates robust progress across a diverse and promising clinical pipeline, with multiple significant data readouts anticipated within the next 18 months. The company has extended its cash runway into 2027, significantly de-risking near-term funding concerns. The strategic prioritization of obesity for NMRA-215 and the advancement of the M4 PAM franchise for schizophrenia address large markets with high unmet needs. The reduction in net loss and R&D expenses also demonstrates improved financial discipline. These factors collectively point to strong operational momentum and significant potential for value creation, making it an attractive investment for a seasoned investor.

Keywords

Biopharmaceutical, Neuroscience, Clinical-stage, Drug development, Schizophrenia, Obesity, Alzheimer's disease, Major depressive disorder, M4 PAM, NLRP3 inhibitor, NMRA-861, NMRA-215, Navacaprant, NMRA-511, Financial results, Pipeline update